

# Toward the Total Synthesis of Alpkindine: Synthesis of Haloquinone CE Ring System Synthons and Attempted Nucleophilic Bisannulation

Marco Buccini, Louisa Tham, Francis Dhoro, Brian W. Skelton, Craig M. Williams, and Matthew J. Piggott\*



Cite This: *ACS Omega* 2022, 7, 19080–19092



Read Online

ACCESS |




Metrics & More



Article Recommendations



Supporting Information



**ABSTRACT:** Model chemistry involving the bisannulation of 2,3-dichloro-1,4-naphthoquinone with the ester enolate derived from ethyl *o*-nitrophenylacetic acid, which rapidly assembled the ABCD ring system of a pentacyclic pyrroloacridine, has been applied to the attempted synthesis of the marine natural product alpkindine. The reaction of ethyl *o*-nitrophenylacetic acid with 6,7-dichloro-2-methylisoquinoline-1,5,8(2*H*)-trione, required to extend the model strategy to alpkindine, was unfruitful, giving only complex mixtures. Efforts to direct the regiochemistry of the key Michael substitution step using 6-bromo-2-methylisoquinoline-1,5,8(2*H*)-trione afforded an adduct sharing the complete carbon skeleton of alpkindine, but this could not be elaborated to the natural product.

## INTRODUCTION

The natural product alpkindine (**1**) (Figure 1), which was isolated from the Indonesian marine sponge *Xestospongia carbonaria* in 2002,<sup>1</sup> is the only D-ring-oxygenated member of a small class of alkaloids possessing a rare pyrroloacridine core. The other congeners, plakinidines A–E (**2**–**6**), were also obtained from Indo-Pacific sponges<sup>2–4</sup> and ascidians,<sup>5,6</sup> although their biosynthetic origin is likely microbial.<sup>5</sup>

Alpkindine was shown to be selectively toxic to solid tumor-derived cell lines over normal cells,<sup>1</sup> and the plakinidines are cytotoxic to a variety of cancer cell lines.<sup>4</sup> Plakinidines A and B also have anthelmintic activity.<sup>2</sup> However, assessment of the biological activity of the pyrroloacridines is limited, presumably due to material scarcity. In contrast, the related pyridoacridines have been widely studied. Nearly all are cytotoxic as a result of their interactions with DNA,<sup>7</sup> and a range of other biological activities have been described, including antibiotic,<sup>8</sup> antifungal,<sup>9</sup> antiviral,<sup>10</sup> antiparasitic,<sup>11</sup> insecticidal,<sup>12</sup> and anti-tumor.<sup>13</sup> Neoamphimedine (**7**) (Figure 1), which is a cometabolite of alpkindine in *X. carbonaria*,<sup>1</sup> is of particular relevance due to its structural similarity to alpkindine and its promising biological activity. An inhibitor of DNA topoisomerase II $\alpha$ , neoamphimedine (**7**), is cytotoxic to yeast and a wide variety of mammalian cell lines.<sup>1,14–16</sup> In one study, it was equipotent with the clinical chemotherapeutic etoposide at inhibiting the growth of xenograft tumors in mice,<sup>16</sup> making it a lead compound for cancer chemotherapy.

The potential for useful biological activity and the unique structures of pyrroloacridine natural products have attracted the interest of several synthetic chemists. In 2004, Kitahara et al.<sup>17</sup> reported the synthesis of a hybrid pyrroloacridine **9** possessing the D ring of alpkindine and the E ring of plakinidine C, but lacking the C7 substituent present in the natural products, in nine steps from **8** (Scheme 1). Beginning with *o*-aminoacetophenone (**10**), Fukuyama and co-workers detailed a 20-step synthesis of a similar hybrid, **11**, which is nitrogenated at C7 but has an incompletely elaborated E ring.<sup>18</sup> Tokuyama et al. have also tackled the plakinidine core, achieving the synthesis of a partially reduced ABCD ring system **13** in 10 steps from precursor **12**.<sup>19</sup>

We previously reported the concise synthesis of the model compound **21**, containing the ABCD ring system of alpkindine, from 2,3-dichloronaphthoquinone (**14**) (Scheme 2).<sup>20</sup> Conjugate substitution with the carbanions derived from ethyl *o*-nitrophenylacetate (**15**) or protected oxindole **16** gave intermediates **17** and **18**, respectively. A cascade reaction involving conjugate substitution of methylamine, then

Received: April 7, 2022

Accepted: May 13, 2022

Published: June 1, 2022








Figure 1. Structures of alpinkidine and related marine alkaloids.

Scheme 1. Previous Syntheses of Pyrroloacridines Related to Alpinkidine and the Plakinidines




Scheme 2. Construction of the ABCD Ring System of Alpinkidine<sup>20</sup>



intramolecular acyl transfer, provided lactams **19** and **20**, which upon unmasking of the anilino group, cyclodehydrated to give **21**.

Tilve and co-workers subsequently developed a synthesis of **21** (Scheme 3).<sup>21</sup> The quinolyl chloride **23**, prepared from

Scheme 3. Tilve and Co-Workers' Synthesis of **21**<sup>21</sup>




isatin (**22**) in seven steps,<sup>22</sup> underwent a high-yielding Negishi coupling with arylzinc **24** to give biaryl **25**. Dieckmann-like condensation then provided the target pentacycle **21**.

Herein, we provide a full account of our efforts to develop and apply the model chemistry depicted in Scheme 2 to the synthesis of alpinkidine.

## RESULTS AND DISCUSSION

**Model Chemistry.** Our initial objective for this project was to efficiently access the ABCD ring system of alpinkidine. We established that this was possible through the chemistry depicted in Scheme 4.<sup>20</sup> Conjugate substitution of 2,3-dichloronaphthoquinone (**14**) with the carbanion derived from nitrile **26**, followed by treatment of the resultant adduct **27** with methylamine, afforded aminopyrrole **28**. Reductive cyclization followed by aerial oxidation provided pentacycle **29**, with the same ABCD ring scaffold as alpinkidine. However, attempts to oxodeaminate **29** to give the required pyrrolone D ring were unsuccessful. Hence, subsequent

**Scheme 4. First Route to the ABCD Ring System of Alpinkidine<sup>20</sup>**


efforts focussed on nucleophiles that would more directly provide the D ring carbonyl group.

The reaction of **14** with diethyl malonate/sodium ethoxide was previously reported to give Michael substitution product **30** in only 27% yield.<sup>23</sup> However, with a milder base in an aprotic solvent, the efficiency of this reaction was improved considerably (Scheme 5). Two lines of investigation were explored for the elaboration of adduct **30**. First, substitution/lactamization with methylamine to give hydroxypyrrole **31** proceeded smoothly, as expected based on similar precedents.<sup>24,25</sup> However, failure to effectively decarboxylate **31** to give **32** under a variety of conditions thwarted efforts to advance this intermediate. In contrast, acid-catalyzed decarboxylation/cyclization of **30** provided lactone **33** in good yield, but subsequent treatment with methylamine failed to give pyrrolone **32**. Nucleophilic aromatic substitution of *o*-chloronitrobenzene with the carbanion derived from lactone **33** was also investigated but gave a complex mixture of products under a variety of conditions.


Attention then turned to the reaction of **14** with enolate nucleophiles already incorporating the A ring of alpinkidine. As mentioned in the Introduction section, this line of investigation was fruitful, providing two rapid approaches to the model compound **21** (Scheme 2). The reaction of intermediate **17** with other primary amines was also briefly investigated, providing the *N*-2-hydroxyethyl **35** and *N*-benzyl **36** analogues (Scheme 6). In the former case, the crude yield was good, but major losses during purification led to low recovery. An X-ray crystal structure of **35** was obtained (Scheme 6), revealing that the C2–O and C9–O bonds are of similar length and intermediate between standard phenolic C–OH and carbonyl bond lengths, as one might expect for the highly conjugated system. The position of the phenolic hydrogen was not placed, so tautomeric structure **35a** cannot be ruled out, and ergo, **36a** may also be a better representation than **36**. The *N*-benzylpyrrolone **36** underwent reductive cyclization as expected to provide pentacycle **37**. Like the *N*-methyl analogue **21**,<sup>20</sup> **37** was unstable in dimethyl sulfoxide (DMSO)/air but was able to be fully characterized before substantial decomposition occurred.

**Toward Alpinkidine.** Application of the methodology described above to the synthesis of alpinkidine required dichloroisoquinolinetriene **38** (Scheme 7). The reduced symmetry of **38**, compared to that of 1,2-dichloronaphthoquinone (**14**), necessitated a regioselective Michael substitution reaction with the enolate derived from **15**, that is, to provide **39** preferentially. Simple resonance arguments suggest that C7 is likely the more electrophilic of the two chlorinated quinonoid carbons. Nevertheless, taking advantage of the chelating *peri*-dicarbonyl moiety with Lewis acid activation, it might be possible to reverse any such inherent bias. Should **39** be procured, it was anticipated that elaboration to alpinkidine (**1**) via **40** would proceed smoothly, based on the model chemistry.

The synthesis of dichloroquinone **38** began with the commercial benzoic acid **41** (Scheme 8), which may also be conveniently prepared from the cheaper 2,5-dimethoxybenzaldehyde.<sup>26</sup> Conversion to the acid chloride was followed by coupling with secondary amine **42**, prepared in excellent yield by treatment of bromoacetal with excess methylamine. The resulting tertiary amide **43** underwent clean Pomeranz–Fritsch-like cyclization/aromatization<sup>27</sup> to provide isoquinolone **44**. Attempted oxidative demethylation of **44** with ceric ammonium nitrate (CAN) gave an intractable mixture of


**Scheme 5. Preliminary Efforts to Generate the D Ring of Alpinkidine**

**Scheme 6. Elaboration of 17 with Different Amines, Including a Representation of the X-Ray Crystal Structure of 35/35a<sup>a</sup>**




<sup>a</sup>The position of the phenolic proton in 35/35a could not be defined. The molecule is disordered about the ethanolamine portion, with two distinct alcohol environments being calculated for both with an associated molecule of MeOH (omitted for clarity). Displacement envelopes are at 50% probability amplitude, with hydrogen atoms assigned arbitrary radii.

**Scheme 7. Key Precursor 38 and Proposed Route to Alpkindine**



products; hence, stepwise demethylation then oxidation was pursued. A short treatment with molten pyridinium chloride<sup>28,29</sup> (to avoid N-demethylation) provided mono-methyl ether 45 in moderate yield, but again, CAN-mediated oxidative demethylation of this phenol was unsuccessful.

**Scheme 8. Synthesis of Quinone 47**




Fortunately, a slightly longer Prey demethylation allowed very efficient conversion to hydroquinone 46, and quantitative oxidation to quinone 47 was achieved with silver(I) oxide.<sup>30,31</sup> Subsequently, MnO<sub>2</sub><sup>32</sup> was found to be nearly as effective for this oxidation.

In an effort to circumvent the demethylation step, 2,5-diacetoxybenzoic acid (48)<sup>33</sup> was amidated to give 49, which cyclized in concentrated sulfuric acid and deacetylated during aqueous work-up, providing hydroquinone 46. On one occasion, this cyclization gave a near quantitative yield of 46. However, on repetition, much lower yields were obtained, perhaps due to variability in the water content of the sulfuric acid.

With 47 in hand, attention turned to the regioselective dichlorination of the quinone moiety. Shi et al.<sup>34</sup> converted quinone 50 to dichloride 51 using thionyl chloride/pyridine (Scheme 9). Under similar conditions, 47 gave mainly chlorohydroquinone 52a, with a trace of the regioisomer 52b. The formation of the hydroquinone likely reflects the greater reduction potential of the electron-deficient quinone 47 (and its monochlorinated derivatives), relative to 50/51. The identity of the reductant is unclear, but may be sulfur monoxide, a byproduct of the chlorination reaction.<sup>34</sup> The mixture of hydroquinones 52a/b was oxidized, and X-ray crystallography revealed a 94:6 cocrystal of quinones 53a/b, respectively (Scheme 9).


Quinone 47 reacted with sulfonyl chloride/triethylamine<sup>35</sup> to give the desired dichloride 38, albeit in very poor yield, accompanied by trichloride 54 and an intractable mixture of other products (Scheme 10). Nevertheless, this provided enough material to test the key Michael substitution reaction. Alas, the reaction of 38 with the carbanion derived from ethyl *o*-nitrophenylacetate (15) gave none of the expected adduct

**Scheme 9. Attempted Synthesis of 38, Including a Representation of the X-ray Crystal Structure of 53a/b (a 94:6 Cocrystal Structure)<sup>a</sup>**



<sup>a</sup>Displacement envelopes are at 50% probability amplitude with hydrogen atoms assigned arbitrary radii.

**Scheme 10. Low Yielding Chlorination and Failed Michael Substitution**



39. No other identifiable products were observed, providing little information as to why this reaction failed when the model chemistry (Scheme 2) worked so well.

In an attempt to salvage this route and address the regiochemical challenge in linking the CE and ABD ring systems of alpinkidine, monohalogenated quinones, in which the halogen could direct Michael substitution to the 6-position, were targeted. Both bromide **67** and iodide **68** were prepared to test this hypothesis, as outlined in Scheme 11. Bromination or iodination<sup>36</sup> of commercial 2,5-dimethox-

ytoluene (**55**) gave **56**<sup>37</sup> and **57**, respectively. Permanganate oxidation to benzoic acids **58**<sup>38</sup>/**59** was followed by amidation of the derived acid chlorides with methylaminoacetal **42**, providing **60**/**61**, respectively. Cyclization with sulfuric acid to give isoquinolones **62**/**63** was complicated by partial, regioselective demethylation, also affording **64**/**65**, respectively. The structure of bromide **64** was confirmed by X-ray crystallography. The halogens clearly play a role here as no such demethylation was observed in reaction of the nonhalogenated analogue (**43**  $\rightarrow$  **44**, Scheme 8). Precedents for similar demethylations of *ortho*-bromoanisoles by sulfuric acid exist.<sup>39–41</sup> While initially annoying, this side reaction turned out to be fortuitous as attempts to oxidatively demethylate **62**/**63** gave complex mixtures of indiscernible products and efforts to fully demethylate iodide **63** under more standard conditions were similarly unsuccessful. In contrast, oxidative demethylation of monomethyl ethers **64**/**65** gave acceptable yields of the target quinones **67**/**68**, respectively. Interestingly, iodide **68** crystallized from DMSO-*d*<sub>6</sub> solution (NMR sample) as a monosolvate exhibiting halogen bonding (Scheme 11).


Unfortunately, the reaction of iodide **68** with ethyl *o*-nitrophenyl acetate (**15**) under basic conditions furnished neither the expected Michael substitution product **69** (Scheme 12) nor any other identifiable compounds. In contrast, the corresponding reaction of bromide **67** gave a discrete new spot by TLC. However, upon isolation, this product was identified as hydroquinone **70**, which presumably arises by reduction of the expected Michael substitution product **69**. The nature of the reductant can only be speculated upon, as no other products could be isolated or identified among the complex mixture. Reactions of bromoquinones with C-nucleophiles are known to be complicated by *cine* addition competing with *ipso*-substitution.<sup>42–47</sup> Thus, *cine* addition of the carbanion derived from **15** to **67** would give rise to hydroquinone **71**, which could reduce the *ipso* substitution product **69** to **70**. The byproduct, quinone **72**, might then take part in subsequent reactions, giving rise to the complex mixture of products observed.

Despite the low yield, the production of **70** was a promising advance in developing a synthesis of alpinkidine using our bisannulation strategy. Hence, **70** was oxidized with silver(I) oxide with the expectation that quinone **73** might be elaborated to alpinkidine (**1**) (Scheme 13). However, **73** was not detected in the crude product of this reaction, as evidenced by the lack of a quinonoid methine resonance in the <sup>1</sup>H NMR spectrum. The appearance of a downfield signal, consistent with a hydrogen-bonded phenolic hydroxyl, suggests that quinone **73** might have tautomerized to *o*-quinonemethide **74** (and or its *Z* isomer), but scarcity of material prevented conclusive identification of this product. Indeed, this complication, along with the disappointing yield of the previous step, and the perceived difficulty in carrying **74** forward to alpinkidine, made this route unappealing, and hence, it was abandoned.


## CONCLUSIONS

Two approaches to connect the CE ring system and A ring of the pentacyclic pyrroloacridine natural product alpinkidine (**1**), through construction of the BD rings using Michael substitution of haloquinonoid isoquinolinetrienes, have been explored (Scheme 14). Chemistry that efficiently afforded the



Scheme 11. Synthesis of 6-Haloisoquinolinetriones, including Representations of the X-Ray Crystal Structures of **64** and **68**<sup>a</sup>

<sup>a</sup>Displacement envelopes are at 50% probability amplitude with hydrogen/deuterium atoms assigned arbitrary radii. The I...O halogen bond between **68** and DMSO-d<sub>6</sub> is indicated in light blue.

Scheme 12. Unexpected Reductive Substitution of and Hypothetical Competing *Cine* Addition to **67**

model pentacyclic pyrroloacridine **21**, lacking only the E ring of alpinkidine, failed to translate to the “real system”. The novel isoquinolinetrione **47**, which may also prove useful for the synthesis of neoamphimedine and analogues, was prepared efficiently. This intermediate could be chlorinated, albeit in very low yield, but reactions of dichloroquinone **38** with **15** under basic conditions gave only complex mixtures.

Attempts to direct the regiochemistry of Michael substitution reactions using 6-haloisoquinolinetriones (e.g., **67**) were also explored. This strategy afforded adduct **70**, comprising the complete carbon-connectivity of alpinkidine (**1**). However, attempts to elaborate this scaffold to the required heterocyclic ring system failed.

Given these setbacks, our attention turned to Michael additions (as opposed to substitutions) to construct the key carbon–carbon bond that is ultimately shared by the BD


rings in alpinkidine (**1**). These endeavors are reported in the following paper.

## EXPERIMENTAL SECTION

**General.** General experimental details are as reported previously.<sup>20,48</sup>

**Synthesis.** Diethyl 2-(3-Chloro-1,4-dioxo-1,4-dihydro-naphthalen-2-yl)malonate (**30**).<sup>23</sup> 2,3-Dichloro-1,4-naphthoquinone (**14**) (1.14 g, 5.03 mmol) was added to a stirred suspension of diethylmalonate (1.6 mL, 10 mmol) and K<sub>2</sub>CO<sub>3</sub> (1.4 g, 10 mmol) in dimethylformamide (DMF) (80 mL) and heated to 45 °C. After 1.5 h, the reaction mixture was cooled, acidified with 1 M HCl (20 mL), extracted with EtOAc (3 × 20 mL), dried and evaporated, and the crude residue was subjected to chromatography. Elution with 1:9 EtOAc/hexanes gave **30** (1.46 g, 83%) as a pale green solid, mp 102–104 °C [lit.<sup>23</sup> 102 °C]. <sup>1</sup>H NMR (400 MHz,

**Scheme 13. Oxidation of Hydroquinone 70 and Putative Tautomerization Preventing the Formation of the Alpinidine D Ring**



CDCl<sub>3</sub>):  $\delta$  8.21–8.12 (m, 2H, 2 $\times$  ArH), 7.82–7.76 (m, 2H, 2 $\times$  ArH), 5.12 (s, 1H, H2), 4.32–4.23 (m [app dq], 4H, 2 $\times$  CH<sub>2</sub>), 1.28 (t,  $J$  = 7.1 Hz, 6H, 2 $\times$  CH<sub>3</sub>). The <sup>1</sup>H NMR data were consistent with the literature.<sup>23</sup>


**Ethyl 2-Hydroxy-1-methyl-4,9-dioxo-4,9-dihydro-1H-benzo[f]indole-3-carboxylate (31).** Ethanolic MeNH<sub>2</sub> (0.13 mL, 1.04 mmol) was added to a solution of **30** (0.17 g, 0.50 mmol) in EtOH (5 mL) at 0 °C. After 1.5 h, the solution was poured into 1 M HCl (10 mL), extracted with EtOAc (3  $\times$  10 mL), dried, and evaporated. The crude solid was precipitated from dichloromethane (DCM)/hexanes to give **31** (0.12 g, 83%) as a pale-yellow/orange solid. <sup>1</sup>H NMR (600 MHz):  $\delta$  11.4 (s, 1H, OH), 8.13 (m, 1H, H5 or H8), 8.07 (m, 1H, H5 or H8), 7.65 (m, 2H, H6 & H7), 4.70 (q,  $J$  = 7.2 Hz, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 3.93 (s, 3H, NMe), 1.50 (t,  $J$  = 7.2 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>). <sup>13</sup>C NMR (150 MHz):  $\delta$  179.1 (C4 or C9), 176.2 (C4 or C9), 168.6 (CO<sub>2</sub>), 159.3 (C2), 133.4

(C4a or C8a), 133.1 (C6 or C7), 132.9 (C6 or C7), 132.5 (C4a or C8a), 126.7 (C5 or C8), 125.5 (C5 or C8), 125.6 (C9a), 123.5 (C3a), 91.2 (C3), 61.7 (OCH<sub>2</sub>CH<sub>3</sub>), 30.8 (NMe), 14.3 (OCH<sub>2</sub>CH<sub>3</sub>). This compound was synthesized in 1930 from the bromide analogue of **30** and described as yellow needles.<sup>49</sup>

**Naphtho[2,3-*b*]furan-2,4,9(3*H*)-trione (33).** A suspension of **30** (0.44 g, 1.25 mmol) in AcOH (30 mL) and 6 M HCl (30 mL) was heated under reflux. After 24 h, the reaction mixture was cooled, neutralized with sat. aq NaHCO<sub>3</sub> (100 mL), extracted with EtOAc (5  $\times$  20 mL), dried, and evaporated. The crude solid was then washed with DCM/hexanes to give **33** (0.25 g, 93%) as a brown solid, mp 240–245 °C.  $R_f$  (1:9 MeOH/DCM) 0.2. IR (ATR)  $\nu_{\max}$  cm<sup>-1</sup>: 1704 (C=O), 1668 (C=O). <sup>1</sup>H NMR (600 MHz):  $\delta$  8.18 (m, 1H, ArH), 8.14 (m, 1H, ArH), 7.78 (m, 2H, ArH), 3.94 (s, 3H, H3). <sup>13</sup>C NMR (150 MHz):  $\delta$  181.7 (C4 or C9), 177.4 (C4 or C9), 172.9 (C2), 145.6 (C9a), 140.4 (C3a or C4a or C8a), 134.6 (ArH), 134.4 (ArH), 131.4 (C3a or C4a or C8a), 131.4 (C3a or C4a or C8a), 127.5 (ArH), 127.3 (ArH), 33.5 (C3). HRMS (APCI): calcd for C<sub>12</sub>H<sub>7</sub>O<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup>, 215.0348; found, 215.0339.

**9-Hydroxy-1-(2-hydroxyethyl)-3-(2-nitrophenyl)-1H,2H,4H-benzo[f]indole-2,4-dione (35/35a).** A solution of ethanolamine (0.15 mL, 2.48 mmol) in H<sub>2</sub>O (1 mL) was added to a stirred solution of **17**<sup>20</sup> (0.11 g, 0.27 mmol) in EtOH (5 mL). After 30 min, the reaction mixture was diluted with aqueous 10% citric acid (20 mL) and extracted with EtOAc (3  $\times$  10 mL). The organic phase was extracted with sat. aq NaHCO<sub>3</sub> (3  $\times$  10 mL). The aqueous phase was acidified with 1 M HCl (50 mL), extracted with EtOAc (3  $\times$  30 mL), dried, and evaporated to give **35/35a** (27 mg, 27%) as a purple solid, mp 122–125 °C.  $R_f$  (1:20:80 AcOH/MeOH/DCM) 0.3. IR (ATR)  $\nu_{\max}$  cm<sup>-1</sup>: 3500–2500 (OH), 1712 (C=O), 1658 (C=O), 1630 (C=O). <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.09 (d,  $J$  = 8.4 Hz, 1H, ArH), 7.97 (d,  $J$

**Scheme 14. Summary of Key Approaches Investigated**



= 7.8 Hz, 1H, ArH), 7.79 (d,  $J$  = 7.2 Hz, 1H, ArH), 7.72 (m, 2H, ArH), 7.65 (dd [app. t],  $J_1 = J_2$  = 7.2 Hz, 1H, ArH), 7.59 (dd [app. t],  $J_1 = J_2$  = 7.2 Hz, 1H, ArH), 7.55 (d,  $J$  = 7.2 Hz, 1H, ArH), 4.46 (s, 1H, NCH<sub>2</sub>), 4.40 (s, 1H, NCH<sub>2</sub>), 3.72 (t,  $J$  = 6.6 Hz, 2H, CH<sub>2</sub>O). <sup>13</sup>C NMR (150 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  180.4 (C4), 171.3 (C9), 151.1 (C2), 149.1 (C2'), 133.8 (CH), 133.7, 133.5 (CH), 132.9 (CH), 132.5, 128.5 (CH), 127.2, 125.5 (CH), 124.3 (CH), 123.7, 122.5, 101.6 (C3), 59.7 (CH<sub>2</sub>), 45.4 (CH<sub>2</sub>). HRMS (APCI): calcd for C<sub>20</sub>H<sub>15</sub>N<sub>2</sub>O<sub>6</sub><sup>+</sup> [ $M + H$ ]<sup>+</sup>, 379.0939; found, 379.0925.

**1-Benzyl-9-hydroxy-3-(2-nitrophenyl)-1H,2H,4H-benzo[f]-indole-2,4-dione (36/36a).** A solution of benzylamine (0.30 mL, 2.7 mmol) in H<sub>2</sub>O (1 mL) was added to a stirred solution of **17**<sup>20</sup> (0.11 g, 0.27 mmol) in EtOH (5 mL). After 30 min, the reaction mixture was diluted with aqueous 10% citric acid (20 mL), extracted with EtOAc (3  $\times$  10 mL), dried, and evaporated. Precipitation from a mixture of MeOH/DCM/hexanes gave **36/36a** (89 mg, 77%) as a red solid, mp 110–113 °C.  $R_f$  (1:4 MeOH/DCM) 0.25. IR (ATR)  $\nu_{\max}$  cm<sup>-1</sup>: 3500–2500 (OH), 1639 (C=O). <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.12 (m [app. d],  $J$  = 5.4 Hz, 1H, ArH), 7.94 (m [app. dd],  $J_1 = 4.2$ ,  $J_2 = 1.8$  Hz, 1H, ArH), 7.81 (d,  $J$  = 7.2 Hz, 1H, ArH), 7.77–7.67 (m, 2H, ArH), 7.67–7.55 (m, 2H, ArH), 7.34 (dd [app. t],  $J_1 = J_2$  = 7.2 Hz, 2H, PhH), 7.26 (m, 3H, PhH), 5.62 (s, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (150 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  180.5 (C4), 171.9 (C9), 151.0 (C2), 149.3 (C2'), 137.5, 134.1, 133.6, 133.1, 132.7, 128.7 (PhH), 127.3 (PhH), 126.8 (PhH), 125.6, 124.4, 124.1, 122.3, 101.6 (C3), 46.2 (CH<sub>2</sub>). HRMS (ESI<sup>+</sup>): calcd for C<sub>25</sub>H<sub>15</sub>N<sub>2</sub>O<sub>5</sub><sup>+</sup> [ $M - H$ ]<sup>+</sup>, 423.0989; found, 423.0986.

**6-Benzyl-7-hydroxybenzo[c]pyrrolo[4,3,2-mn]acridin-5(6H)-one (37).** Iron powder (0.19 g, 3.4 mmol) was added to a vigorously stirred solution of **36** (0.13 g, 0.31 mmol) in AcOH (7 mL), H<sub>2</sub>O (3 mL), and MeOH (2 mL). After 2.5 h, the reaction mixture was diluted with H<sub>2</sub>O (20 mL), extracted with EtOAc (3  $\times$  20 mL), dried, and evaporated. Precipitation from a mixture of MeOH/DCM/hexanes followed by recrystallization from EtOH gave **37** (74 mg, 63%) as a purple solid, mp 262–265 °C.  $R_f$  (1:19 MeOH/DCM) 0.25. IR (ATR)  $\nu_{\max}$  cm<sup>-1</sup>: 3200–2800 (OH), 1661 (C=O), 1606 (C=O). <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  7.87 (dd,  $J_1 = 7.2$ ,  $J_2 = 3.0$  Hz, 2H, ArH), 7.75 (d,  $J$  = 7.8 Hz, 1H, ArH), 7.64 (dd [app. t],  $J_1 = J_2$  = 7.8 Hz, 1H, ArH), 7.58 (dd [app. t],  $J_1 = J_2$  = 7.8 Hz, 1H, ArH), 7.33 (m, 3H, ArH), 7.30–7.24 (m, 4H, ArH), 7.21 (dd [app. t],  $J_1 = J_2$  = 7.2 Hz, 1H, ArH), 5.52 (s, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (150 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  181.3 (C7), 159.7 (C5), 139.4 (C11b), 135.0, 133.9, 133.3, 132.6, 131.8, 130.5, 129.0, 128.7 (PhH), 127.8 (PhH), 127.3, 126.9, 126.0, 125.8, 125.3, 124.9, 123.0, 122.9, 101.4 (C4b), 45.2 (CH<sub>2</sub>). HRMS (ESI<sup>+</sup>): calcd for C<sub>25</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub><sup>+</sup> [ $M + H$ ]<sup>+</sup>, 377.1296; found, 377.1285.

**2,2-Diethoxy-N-methylethanamine (42).** Bromoacetaldehyde diethyl acetal (15 mL, 97 mmol) was added to a stirred solution of 40% aqueous MeNH<sub>2</sub> (90 mL, 0.11 mol) in MeOH (120 mL). The reaction mixture was heated under gentle reflux for 12 h before being cooled, diluted with brine (150 mL), and extracted with EtOAc (3  $\times$  100 mL). The extracts were washed with brine and evaporated. Distillation of the residue at reduced pressure gave the secondary amine **42** as a clear, colorless oil (13.9 g, 94%), bp 77–79 °C@20 mm Hg. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  4.50 (t,  $J$  = 5.6 Hz, 1H, H2) 3.67–3.55 (m, 2H, CH<sub>2</sub>O), 3.51–3.40 (m, 2H, CH<sub>2</sub>O), 2.60 (d,  $J$  = 5.6 Hz, 2H, H1), 2.35 (s, 3H, NMe),

1.12 (t,  $J$  = 7.1 Hz, 6H, 2 $\times$  CH<sub>3</sub>). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  101.9 (C2), 62.2 (2 $\times$  CH<sub>2</sub>O), 54.1 (C1), 36.3 (NCH<sub>3</sub>), 15.2 (2 $\times$  CH<sub>3</sub>). The synthesis of this compound has been described previously, but not by this method, and NMR data have not been reported.<sup>50</sup>

**N-(2,2-Diethoxyethyl)-2,5-dimethoxy-N-methylbenzamide (43).** A solution of 2,5-dimethoxybenzoic acid (**41**)<sup>26</sup> (5.71 g, 31.3 mmol) and SOCl<sub>2</sub> (10 mL, 0.14 mol) in DCM (25 mL) was heated under reflux for 2 h before the solvent and excess SOCl<sub>2</sub> were evaporated. The residue was cooled to 0 °C, and a solution of pyridine (10 mL, 0.12 mol) in DCM (10 mL) was added dropwise, followed by the dropwise addition of a solution of **42** (7.32 g, 49.7 mmol) in DCM (10 mL). The mixture was stirred at room temperature (rt) for 3 h before being diluted with H<sub>2</sub>O (50 mL) and extracted with DCM (3  $\times$  20 mL). The extract was washed with sat. aq NaHCO<sub>3</sub> (20 mL), dried, and evaporated, and the crude product was subjected to flash chromatography. Elution with 2:3 EtOAc/hexanes gave **43** (9.25 g, 95%) as a clear colorless oil.  $R_f$  (3:2 EtOAc/hexanes) 0.35. IR (ATR)  $\nu_{\max}$  cm<sup>-1</sup>: 1634 (C=O). <sup>1</sup>H NMR (600 MHz CDCl<sub>3</sub>; a 9:5 mixture of major and minor\* rotamers):  $\delta$  6.87–6.80 (m, 2H, ArH), 6.78 \*(d,  $J$  = 3.0 Hz, 1H, ArH), 6.76 (d,  $J$  = 3.0 Hz, 1H, ArH), 4.80 (t,  $J$  = 5.4 Hz, 1H, H2'), 4.42 \*(t,  $J$  = 5.4 Hz, 1H, H2'), 3.81–3.77 (m, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 3.76 (s, 3H, OMe), 3.75 (s, 3H, OMe), 3.74 \*(s, 3H, OMe), 3.65–3.58 (m, 3H, OCH<sub>2</sub>CH<sub>3</sub> & H1'), 3.57–3.50 \*(m, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 3.57–3.50 (m, 1H, H1'), 3.33 \*(m, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 3.29–3.26 \*(m, 1H, H1'), 3.22–3.19 \*(m, 2H, H1'), 3.15 \*(s, 3H, NMe), 2.91 (s, 3H, NMe), 1.23 (t,  $J$  = 7.2 Hz, 6H, OCH<sub>2</sub>CH<sub>3</sub>), 1.12 \*(t,  $J$  = 7.2 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>). <sup>13</sup>C NMR (150 MHz):  $\delta$  169.6 \*(C=O), 169.4 (C=O), 153.8 (C2 or C5), 149.4 (C2 or C5), 149.1 \*(C2 or C5), 127.2 (C1), 127.0 \*(C1), 115.5 \*(ArH), 115.4 (ArH), 113.6 \*(ArH), 113.2 (ArH), 112.5 \*(ArH), 112.3 (ArH), 102.1 \*(C2'), 101.4 (C2'), 63.8 (OCH<sub>2</sub>CH<sub>3</sub>), 63.6 (OCH<sub>2</sub>CH<sub>3</sub>), 63.4 \*(OCH<sub>2</sub>CH<sub>3</sub>), 63.2 \*(OCH<sub>2</sub>CH<sub>3</sub>), 56.2 \*(OMe), 56.1 (OMe), 55.9 (OMe), 53.6 \*(C1'), 51.0 (C1'), 38.4 (NMe), 34.6 \*(NMe), 15.5 (OCH<sub>2</sub>CH<sub>3</sub>), 15.3 \*(OCH<sub>2</sub>CH<sub>3</sub>). HRMS (APCI): calcd for C<sub>16</sub>H<sub>26</sub>NO<sub>5</sub><sup>+</sup> [ $M + H$ ]<sup>+</sup>, 312.1798; found, 312.1805.

**5,8-Dimethoxy-2-methylisoquinolin-1(2H)-one (44).** Concentrated H<sub>2</sub>SO<sub>4</sub> (10 mL) was added dropwise to neat **43** with stirring at 0 °C. After the addition was complete, the solution was warmed to 40 °C for 24 h under a CaCl<sub>2</sub> guard tube. The solution was cooled, carefully neutralized with ice cold sat. aq NaHCO<sub>3</sub> (~50 mL), until effervescing ceased, then extracted with EtOAc (3  $\times$  30 mL). The extract was dried and evaporated. Precipitation from EtOAc/hexanes gave **44** as an off-white solid (5.54 g, 96%), mp 143–148 °C.  $R_f$  (EtOAc) 0.15. IR (ATR)  $\nu_{\max}$  cm<sup>-1</sup>: 1654 (C=O). <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  7.38 (d,  $J$  = 7.8 Hz, 1H, H3), 7.14 (d,  $J$  = 9.0 Hz, 1H, H6 or H7), 6.89 (d,  $J$  = 9.0 Hz, 1H, H6 or H7), 6.64 (d,  $J$  = 7.8 Hz, 1H, H4), 3.84 (s, 3H, OMe), 3.74 (s, 3H, OMe), 3.38 (s, 3H, NMe). <sup>13</sup>C NMR (150 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  160.0 (C1), 153.8 (C5 or C8), 147.5 (C5 or C8), 134.2 (C3), 130.3 (C4a or C8a), 115.6 (C4a or C8a), 113.1 (C6 or C7), 109.2 (C6 or C7), 98.6 (C4), 56.5 (OMe), 56.3 (OMe), 36.9 (NMe). HRMS (APCI): calcd for C<sub>12</sub>H<sub>14</sub>NO<sub>3</sub><sup>+</sup> [ $M + H$ ]<sup>+</sup>, 220.0959; found, 220.0968.

**8-Hydroxy-5-methoxy-2-methylisoquinolin-1(2H)-one (45).** Neat **44** (45 mg, 0.20 mmol) was added to pyridine



hydrochloride\*; the mixture was heated under reflux for 10 min before being diluted with H<sub>2</sub>O (20 mL), extracted with EtOAc (3 × 10 mL), dried, and evaporated, and the crude product was subjected to flash chromatography. Elution with 3:2 EtOAc/hexanes gave **45** (24 mg, 57%) as an off-white solid, mp 75–78 °C. *R*<sub>f</sub> (2:3 EtOAc/hexanes) 0.25. IR (ATR)  $\nu_{\max}$  cm<sup>-1</sup>: 3200–2800 (OH), 1657 (C=O). <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  12.4 (s, 1H, OH), 7.45 (d, *J* = 7.2 Hz, 1H, ArH), 7.19 (d, *J* = 8.4 Hz, 1H, ArH), 6.78 (d, *J* = 7.2 Hz, 1H, ArH), 6.76 (d, *J* = 8.4 Hz, 1H, ArH), 3.83 (s, 3H, OMe), 3.52 (s, 3H, NMe). <sup>13</sup>C NMR (150 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  164.9 (C1), 153.6 (C5 or C8), 145.7 (C5 or C8), 133.1 (ArH), 127.6 (C4a or C8a), 115.5 (ArH), 111.5 (C4a or C8a), 111.4 (ArH), 101.3 (ArH), 56.2 (OMe), 36.0 (NMe). HRMS (APCI): calcd for C<sub>11</sub>H<sub>12</sub>NO<sub>3</sub><sup>+</sup> [*M* + *H*]<sup>+</sup>, 206.0833; found, 206.0812.

\*Pyridine hydrochloride was prepared from pyridine (2 mL) and concentrated HCl (2.5 mL) as detailed in the preparation of **46** below.

**5,8-Dihydroxy-2-methylisoquinolin-1(2H)-one (46).** Method 1: Concentrated HCl (25 mL) was added dropwise to pyridine (20 mL) at 0 °C. After the addition was complete, excess H<sub>2</sub>O and pyridine were removed by distillation, leaving pyridine hydrochloride as a white solid. Neat **44** (0.58 g, 2.67 mmol) was added, and the mixture was heated under reflux for 20 min, then cooled, diluted with H<sub>2</sub>O (30 mL), and extracted with EtOAc (3 × 20 mL). The extract was dried and evaporated to give **46** (0.49 g, 97%) as an off-white solid, mp 180–185 °C. *R*<sub>f</sub> (3:2 EtOAc/hexanes) 0.3. IR (ATR)  $\nu_{\max}$  cm<sup>-1</sup>: 3200–3000 (OH), 1652 (C=O). <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  12.3 (s, 1H, OH), 9.48 (s, 1H, OH), 7.38 (d, *J* = 7.8 Hz, 1H, ArH), 7.02 (d, *J* = 8.4 Hz, 1H, ArH), 6.77 (d, *J* = 7.8 Hz, 1H, ArH), 6.65 (d, *J* = 8.4 Hz, 1H, ArH), 3.50 (s, 3H, NMe). <sup>13</sup>C NMR (150 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  164.9 (C1), 152.5 (C5 or C8), 143.5 (C5 or C8), 132.0 (ArH), 126.1 (C4a or C8a), 118.8 (ArH), 111.7 (ArH), 111.2 (C4a or C8a), 101.8 (ArH), 35.7 (NMe). HRMS (APCI): calcd for C<sub>10</sub>H<sub>10</sub>NO<sub>3</sub><sup>+</sup> [*M* + *H*]<sup>+</sup>, 192.0641; found, 192.0655.

Method 2: Concentrated H<sub>2</sub>SO<sub>4</sub> (2 mL) was added dropwise to **49** (205 mg, 0.558 mmol) with stirring at 0 °C. After the addition was complete, the solution was allowed to warm to rt, then stirring was continued at 50 °C overnight. After 20 h, H<sub>2</sub>O (5 mL) was added, and the solution was stirred for 1 h before being diluted with water (~20 mL) and extracted with EtOAc (3 × 20 mL). The extract was dried and evaporated, and the residue was subjected to flash chromatography. Elution with 2:3 EtOAc/hexanes gave **46** (105 mg, 98%) as an off-white solid, which was identical to the material described above. **Note:** several attempts to repeat this outcome resulted in yields in the range 20–30%.

**2-Methylisoquinoline-1,5,8(2H)-trione (47).** Ag<sub>2</sub>O (2.59 g, 11.2 mmol) was added to a stirred suspension of **46** (0.57 g, 2.47 mmol) and MgSO<sub>4</sub> (1.52 g, 12.6 mmol) in Et<sub>2</sub>O (50 mL). After 20 min, the mixture was filtered through a plug of Celite and washed with DCM (3 × 10 mL). The volatiles were then removed to give **47** (0.47 g, quant.) as a bright red solid, mp 184–189 °C. *R*<sub>f</sub> (EtOAc) 0.15. IR (ATR)  $\nu_{\max}$  cm<sup>-1</sup>: 1661 (C=O). <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.32 (d, *J* = 6.6 Hz, 1H, ArH), 6.97 (d, *J* = 9.6 Hz, 1H, ArH), 6.85 (d, *J* = 9.6 Hz, 1H, ArH), 6.63 (d, *J* = 6.6 Hz, 1H, ArH), 3 (s, 3H, NMe). <sup>13</sup>C NMR (150 MHz, DMSO-

*d*<sub>6</sub>):  $\delta$  185.4 (C5 or C8), 182.7 (C5 or C8), 157.4 (C1), 147.6 (ArH), 142.7 (C4a or C8a), 140.3 (ArH), 134.9 (ArH), 116.6 (C4a or C8a), 99.3 (ArH), 38.1 (NMe). HRMS (APCI): calcd for C<sub>10</sub>H<sub>8</sub>NO<sub>3</sub><sup>+</sup> [*M* + *H*]<sup>+</sup>, 190.0497; found, 190.0499.

**N-(2,2-Diethoxyethyl)-N-methyl-2,5-diacetoxybenzamide (49).** A solution of 2,5-diacetoxybenzoic acid (**48**)<sup>33</sup> (0.31 g, 1.29 mmol) and SOCl<sub>2</sub> (0.30 mL, 4.1 mmol) in PhMe (20 mL) was heated under reflux for 2 h before the solvent and excess SOCl<sub>2</sub> were removed by distillation. The residue was cooled to 0 °C, and a solution of NEt<sub>3</sub> (0.5 mL, 3.61 mmol) in PhMe (10 mL) was added dropwise, followed by the dropwise addition of a solution of **42** (0.25 g, 1.7 mmol) in PhMe (10 mL). The mixture was stirred at rt for another 3 h before being diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 20 mL). The extract was washed with sat. aq NaHCO<sub>3</sub> (20 mL), dried, and evaporated, and the residue was subjected to flash chromatography. Elution with 2:3 EtOAc/hexanes gave **49** (0.24 g, 50%) as a pale-yellow oil. *R*<sub>f</sub> (3:2 EtOAc/hexanes) 0.35. IR (ATR)  $\nu_{\max}$  cm<sup>-1</sup>: 1763 (Ac C=O), 1638 (NC=O). <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>; a 3:2 mixture of major and minor\* rotamers):  $\delta$  7.29–7.19 (m, 2H, H3/4 both rotamers), 7.17 (d, *J* = 2.4 Hz, 1H, H6), 7.12 (d, *J* = 2.4 Hz, 1H, H6), 4.67 (t, *J* = 5.4 Hz, 1H, H2'), 4.51 (t, *J* = 5.4 Hz, 1H, H2'), 3.65 (m, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 3.51 (m, 3H, OCH<sub>2</sub>CH<sub>3</sub> & H1'), 3.14 (d, *J* = 5.4 Hz, 1H, H1'), 2.98 (s, 3H, NMe), 2.82 (s, 3H, NMe), 2.27 (s, 3H, Ac Me), 2.22 (s, 3H, Ac Me), 2.19 (s, 3H, Ac Me), 1.14 (t, *J* = 6.6 Hz, 6H, OCH<sub>2</sub>CH<sub>3</sub>), 1.05 (t, *J* = 6.6 Hz, 6H, OCH<sub>2</sub>CH<sub>3</sub>). <sup>13</sup>C NMR (150 MHz, DMSO-*d*<sub>6</sub>; a 3:2 mixture of major and minor\* rotamers):  $\delta$  169.3 (C=O), 169.2 (C=O), 168.9 (C=O), 168.8 (C=O), 166.4 (C=O), 166.0 (C=O), 147.8 (ArO), 147.6 (ArO), 143.8 (ArO), 143.7 (ArO), 130.8 (C1), 130.7 (C1), 124.4 (ArH), 124.3 (ArH), 123.5 (ArH), 123.4 (ArH), 121.7 (ArH), 120.9 (ArH), 100.5 (C2'), 100.0 (C2'), 62.7 (OCH<sub>2</sub>), 61.5 (OCH<sub>2</sub>), 52.9 (C1'), 49.3 (C1'), 37.8 (NMe), 33.7 (NMe), 20.9 (COCH<sub>3</sub>), 20.8 (COCH<sub>3</sub>), 20.6 (COCH<sub>3</sub>), 20.5 (COCH<sub>3</sub>), 15.3 (CH<sub>2</sub>CH<sub>3</sub>), 15.2 (CH<sub>2</sub>CH<sub>3</sub>). HRMS (APCI): calcd for C<sub>18</sub>H<sub>26</sub>NO<sub>7</sub><sup>+</sup> [*M* + *H*]<sup>+</sup>, 368.1712; found, 368.1704.

**7-Chloro-5,8-dihydroxy-2-methylisoquinolin-1(2H)-one (52a).** SOCl<sub>2</sub> (0.26 mL, 3.6 mmol) was added to a stirred solution of **47** (93 mg, 0.49 mmol) and pyridine (0.40 mL, 4.9 mmol) in PhMe (20 mL) and dimethoxyethane (DME) (5 mL) at 0 °C. The reaction was then heated to 50 °C for 20 min before being cooled, diluted with H<sub>2</sub>O (30 mL), and extracted with EtOAc (3 × 10 mL). The extract was dried and evaporated, and the residue was subjected to chromatography. Elution with 1:4 EtOAc/hexanes gave **52a**, containing ~6% of the regioisomer 6-chloro-5,8-dihydroxy-2-methylisoquinolin-1(2H)-one (**52b**) [NMR data not shown], as a yellow oil (89 mg, 80%). *R*<sub>f</sub> (3:2 EtOAc/hexanes) 0.3. IR (ATR)  $\nu_{\max}$  cm<sup>-1</sup>: 3100–2300 (OH), 1656 (C=O). <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  9.97 (s, 1H, OH), 7.46 (d, *J* = 7.8 Hz, 1H, H3 or H4), 7.11 (s, 1H, H6), 6.79 (d, *J* = 7.8 Hz, 1H, H3 or H4), 3.53 (s, 3H, NMe). <sup>13</sup>C NMR (150 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  164.6 (C1), 148.3 (C5 or C8), 143.9 (C5 or C8), 132.8 (ArCH), 126.0 (C4a or C8a), 118.6 (ArH), 114.2 (C7), 112.1 (C4a or C8a), 101.8 (ArH), 36.2 (NMe). HRMS (APCI): calcd for C<sub>10</sub>H<sub>9</sub><sup>35</sup>ClNO<sub>3</sub><sup>+</sup> [*M* + *H*]<sup>+</sup>, 226.0257; found, 226.0265.

**7-Chloro-2-methylisoquinoline-1,5,8(2H)-trione (53a).** Ag<sub>2</sub>O (0.40 g, 1.7 mmol) was added to a stirred suspension of **52a** (69 mg, 0.31 mmol) and MgSO<sub>4</sub> (0.25 g, 2.1 mmol) in Et<sub>2</sub>O (5 mL) and DME (1 mL). After 20 min, the suspension was filtered through a plug of Celite and washed with DCM (3 × 10 mL). The volatiles were then removed to give **53a**, containing ~6% of the regioisomer 6-chloro-2-methylisoquinoline-1,5,8(2H)-trione (**53b**), as a bright red solid (52 mg, 65%), mp 146–150 °C. *R*<sub>f</sub> (1:19 MeOH/DCM) 0.40; IR (ATR)  $\nu_{\max}$  cm<sup>-1</sup>: 1672 (C=O). <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.38 (d, *J* = 6.6 Hz, 1H, H3 or H4), 7.44 (s, 1H, H6), 6.67 (d, *J* = 6.6 Hz, 1H, H3 or H4), 3.57 (s, 3H, NMe). <sup>13</sup>C NMR (150 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  182.8 (C5 or C8), 174.5 (C5 or C8), 157.2 (C1), 148.3 (ArH), 146.6 (C4a or C8a), 143.1 (C7), 132.9 (ArH), 116.3 (C4a or C8a), 99.5 (ArH), 38.2 (NMe). HRMS (APCI): calcd for C<sub>10</sub>H<sub>7</sub><sup>35</sup>ClNO<sub>3</sub><sup>+</sup> [*M* + *H*]<sup>+</sup>, 224.0112; found, 224.0109.

**6,7-Dichloro-2-methylisoquinoline-1,5,8(2H)-trione (38) and 4,6,7-Trichloro-2-methylisoquinoline-1,5,8(2H)-trione (54).** A solution of **47** (0.26 g, 1.40 mmol) in Et<sub>2</sub>O (5 mL) was added dropwise to a solution of SO<sub>2</sub>Cl<sub>2</sub> (0.45 mL, 5.33 mmol) and NEt<sub>3</sub> (0.20 mL, 1.44 mmol) in Et<sub>2</sub>O (15 mL). Once the addition was complete, the reaction was heated under reflux for 20 h before being cooled, diluted with H<sub>2</sub>O (30 mL), and extracted with EtOAc (3 × 10 mL). The organic component was dried and evaporated, and the crude solid subjected to flash chromatography. Elution with 3:2 EtOAc/hexanes gave **54** as a red solid (25 mg, 6%), mp 216–220 °C. *R*<sub>f</sub> (EtOAc) 0.25. IR (ATR)  $\nu_{\max}$  cm<sup>-1</sup>: 1688 (C=O). <sup>1</sup>H NMR (600 MHz):  $\delta$  7.99 (s, 1H, H3), 3.72 (s, 3H, NMe). <sup>13</sup>C NMR (150 MHz):  $\delta$  175.2 (C5 or C8), 172.7 (C5 or C8), 156.4 (C1), 146.2 (ArH), 143.7 (C4a or C8a), 140.3 (C6 or C7), 138.9 (C6 or C7), 118.5 (C4a or C8a), 108.5 (C4), 39.4 (NMe). HRMS (APCI): calcd for C<sub>10</sub>H<sub>5</sub><sup>35</sup>Cl<sub>3</sub>NO<sub>3</sub><sup>+</sup> [*M* + *H*]<sup>+</sup>, 291.9332; found, 291.9330.

Further elution with EtOAc gave **38** (8 mg, 2%) as a red solid, mp 250–254 °C. *R*<sub>f</sub> (1:99 MeOH/DCM) 0.1. <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  8.38 (d, *J* = 6.6 Hz, 1H, H3 or H4), 6.76 (d, *J* = 6.6 Hz, 1H, H3 or H4), 3.56 (s, 3H, NMe). <sup>13</sup>C NMR (150 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  176.0 (C5 or C8), 172.5 (C5 or C8), 156.9 (C1), 148.0 (C3 or C4), 143.1 (C4a or C8a), 142.9 (C6 or C7), 138.7 (C6 or C7), 115.7 (C4a or C8a), 100.1 (C3 or C4), 38.1 (NMe). HRMS (APCI): calcd for C<sub>10</sub>H<sub>6</sub><sup>35</sup>Cl<sub>2</sub>NO<sub>3</sub><sup>+</sup> [*M* + *H*]<sup>+</sup>, 257.9721; found, 257.9719.

**4-Iodo-2,5-dimethoxytoluene (57).** I<sub>2</sub> (2.5 g, 10 mmol) was added to a stirred suspension of 2,5-dimethoxytoluene (**55**) (1.25 g, 8.21 mmol) and Ag<sub>2</sub>SO<sub>4</sub> (5.4 g, 17 mmol) in EtOH (20 mL). After 24 h, the reaction mixture was filtered, diluted with H<sub>2</sub>O (30 mL), and extracted with EtOAc (3 × 20 mL). The extract was dried and evaporated, and the crude product was subjected to flash chromatography. Elution with 1:9 EtOAc/hexanes gave iodide **57** as a white solid (1.76 g, 77%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.17 (s, 1H, H3 or H6), 6.67 (s, 1H, H3 or H6), 3.82 (s, 3H, OMe), 3.77 (s, 3H, OMe), 2.19 (Me). The <sup>1</sup>H NMR data are identical to those reported.<sup>51</sup>

**4-Bromo-2,5-dimethoxybenzoic Acid (58).**<sup>38</sup> KMnO<sub>4</sub> (2.75 g, 17.4 mmol) was added to a stirred mixture of 1-bromo-2,5-dimethoxy-4-methylbenzene (**56**)<sup>37</sup> (0.73 g, 3.16 mmol) in pyridine (10 mL) and H<sub>2</sub>O (10 mL). After 24 h, the reaction mixture was diluted with 1 M HCl (30 mL),

extracted with EtOAc (3 × 20 mL), dried, and evaporated to give benzoic acid **58** as a white solid (0.58 g, 70%), which was used without further purification. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  12.81 (br s, CO<sub>2</sub>H), 7.37 (s, 1H, H3 or H6), 7.32 (s, 1H, H3 or H6), 3.81 (s, 3H, OMe), 3.78 (s, 3H, OMe). The <sup>1</sup>H NMR spectrum matched the reported data.<sup>52</sup>

**4-Iodo-2,5-dimethoxybenzoic Acid (59).** KMnO<sub>4</sub> (6.05 g, 38.3 mmol) was added to a stirred mixture of **57** (1.76 g, 6.31 mmol) in pyridine (20 mL) and H<sub>2</sub>O (20 mL). After 24 h, the reaction mixture was diluted with 1 M HCl (50 mL) and extracted with EtOAc (3 × 20 mL). The extract was dried and evaporated. Precipitation from EtOAc/hexanes gave benzoic acid **59** as a yellow/white solid (0.69 g, 36%), mp 172–175 °C [lit.<sup>53</sup> 175–177 °C], which was used without further purification in the next step.

**4-Bromo-N-(2,2-diethoxyethyl)-2,5-dimethoxy-N-methylbenzamide (60).** A solution of **58** (3.04 g, 11.7 mmol) and SOCl<sub>2</sub> (1.5 mL, 21 mmol) in PhMe (40 mL) was heated under reflux for 2 h before the solvent and excess SOCl<sub>2</sub> were removed by distillation. The residue was cooled to 0 °C, and a solution of pyridine (1.5 mL, 18 mmol) in PhMe (10 mL) was added dropwise, followed by the dropwise addition of a solution of **42** (2.34 g, 15.9 mmol) in PhMe (10 mL). The mixture was stirred at rt for another 2 h before being diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 20 mL). The extract was washed with sat. aq NaHCO<sub>3</sub> (20 mL), dried, and evaporated, and the residue was subjected to flash chromatography. Elution with 2:3 EtOAc/hexanes gave tertiary amide **60** (3.1 g, 68%) as a pale-yellow oil. *R*<sub>f</sub> (2:3 EtOAc/hexanes) 0.15. IR (ATR)  $\nu_{\max}$  cm<sup>-1</sup>: 1635 (C=O). <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>; a 10:7 mixture of major and minor\* rotamers):  $\delta$  7.33 (s, 1H, H3 or H6), 7.31 \*(s, 1H, H3 or H6), 6.95 \*(s, 1H, H3 or H6), 6.89 \*(s, 1H, H3 or H6), 4.68 (t, *J* = 5.4 Hz, 1H, H2'), 4.48 \*(t, *J* = 5.4 Hz, 1H, H2'), 3.78 (s, 3H, OMe), 3.78 \*(s, 3H, OMe), 3.75 (s, 3H, OMe), 3.74 \*(s, 3H, OMe), 3.71–3.45 (m, 6H, OCH<sub>2</sub>CH<sub>3</sub> & H1'), 3.12 \*(pseudo dd, *J*<sub>1</sub> = 6.0 Hz, *J*<sub>2</sub> = 4.2 Hz, 2H, H1'), 2.99 \*(s, 3H, NMe), 2.80 (s, 3H, NMe), 1.15 (pseudo t [app. s], 6H, OCH<sub>2</sub>CH<sub>3</sub>), 1.04 \*(t, *J* = 6.6 Hz, 6H, OCH<sub>2</sub>CH<sub>3</sub>). <sup>13</sup>C NMR (150 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  167.3 \*(C=O), 167.2 (C=O), 149.6 (C2 or C5), 149.4 \*(C2 or C5), 148.8 (C2 or C5), 148.7 \*(C2 or C5), 126.1 (C1), 125.9 \*(C1), 116.6 (C3 or C6), 116.4 \*(C3 or C6), 112.2 (C4a or C8a), 111.3 (C3 or C6), 111.2 \*(C3 or C6), 111.1 (C4a or C8a), 100.8 (C4), 100.7 \*(C2'), 100.2 (C2'), 62.6 (OCH<sub>2</sub>CH<sub>3</sub>), 62.1 \*(OCH<sub>2</sub>CH<sub>3</sub>), 61.8 (OCH<sub>2</sub>CH<sub>3</sub>), 60.9 \*(OCH<sub>2</sub>CH<sub>3</sub>), 56.6 \*(OMe), 56.5 (OMe), 56.3 (OMe), 56.2 \*(OMe), 52.6 \*(C1'), 49.6 (C1'), 37.3 (NMe), 33.5 \*(NMe), 15.2 (OCH<sub>2</sub>CH<sub>3</sub>), 15.1 \*(OCH<sub>2</sub>CH<sub>3</sub>). HRMS (ESI): calcd for C<sub>18</sub>H<sub>27</sub><sup>79</sup>BrN<sub>2</sub>NaO<sub>5</sub><sup>+</sup> [*M* + Na + MeCN]<sup>+</sup>, 453.0986; found, 453.0996.

**N-(2,2-Diethoxyethyl)-4-iodo-2,5-dimethoxy-N-methylbenzamide (61).** A solution of **59** (0.69 g, 2.24 mmol) and SOCl<sub>2</sub> (5.0 mL, 69 mmol) in PhMe (20 mL) was heated under reflux for 2 h before the solvent and excess SOCl<sub>2</sub> were removed by distillation. The residue was cooled to 0 °C, and a solution of NEt<sub>3</sub> (8.0 mL, 58 mmol) in PhMe (10 mL) was added dropwise, followed by the dropwise addition of a solution of **42** (0.62 g, 4.21 mmol) in PhMe (5 mL). The mixture was stirred at rt for another 24 h before being diluted with H<sub>2</sub>O (50 mL) and extracted with EtOAc (3 × 20 mL). The extract was washed with sat. aq NaHCO<sub>3</sub> (20 mL), dried, and evaporated, and the residue was subjected to

flash chromatography. Elution with 1:4 EtOAc/hexanes gave tertiary amide **61** (0.81 g, 82%) as a pale-yellow oil.  $R_f$  (2:3 EtOAc/hexanes) 0.15. IR (ATR)  $\nu_{\max}$   $\text{cm}^{-1}$ : 1630 (C=O).  $^1\text{H}$  NMR (600 MHz—isolated as a mixture of rotamers, with signals due to the minor rotamer denoted by asterisks):  $\delta$  7.32 (s, 1H, H3 or H6), 7.31 \* (s, 1H, H3 or H6), 6.75 \* (s, 1H, H3 or H6), 6.72 (s, 1H, H3 or H6), 4.80 (t,  $J$  = 5.4 Hz, 1H, H2'), 4.46 \* (t,  $J$  = 5.4 Hz, 1H, H2'), 3.83 (s, 3H, OMe), 3.82 \* (s, 3H, OMe), 3.78 (s, 3H, OMe), 3.77 \* (s, 3H, OMe), 3.72–3.42 (m, 6H,  $\text{OCH}_2\text{CH}_3$  & H1'), 3.38 \* (m, 2H,  $\text{OCH}_2\text{CH}_3$ ), 3.34–3.27 \* (m, 1H, H1'), 3.24–3.17 \* (m, 1H, H1'), 3.15 \* (s, 3H, NMe), 2.92 (s, 3H, NMe), 1.24 (t,  $J$  = 7.2 Hz, 6H,  $\text{OCH}_2\text{CH}_3$ ), 1.15 \* (t,  $J$  = 7.2 Hz, 6H,  $\text{OCH}_2\text{CH}_3$ ).  $^{13}\text{C}$  NMR (150 MHz):  $\delta$  168.9 (C=O), 168.7 (C=O), 152.9 (C2 or C5), 152.8 \* (C2 or C5), 149.7 (C2 or C5), 149.5 \* (C2 or C5), 127.2 (C1), 127.0 \* (C1), 122.8 \* (C3 or C6), 122.7 (C3 or C6), 110.8 \* (C3 or C6), 110.3 (C3 or C6), 101.6 \* (C2'), 101.2 (C2'), 86.7 (C4), 86.6 \* (C4), 63.4 ( $\text{OCH}_2\text{CH}_3$ ), 63.0 ( $\text{OCH}_2\text{CH}_3$ ), 61.8 \* ( $\text{OCH}_2\text{CH}_3$ ), 60.5 \* ( $\text{OCH}_2\text{CH}_3$ ), 57.1 (OMe), 57.0 \* (OMe), 56.5 \* (OMe), 56.4 (OMe), 53.5 \* (C1'), 50.9 (C1'), 38.3 (NMe), 34.3 \* (NMe), 15.5 ( $\text{OCH}_2\text{CH}_3$ ), 15.3 \* ( $\text{OCH}_2\text{CH}_3$ ). HRMS (APCI): calcd for  $\text{C}_{16}\text{H}_{25}\text{INO}_5^+$  [ $\text{M} + \text{H}$ ] $^+$ , 438.0790; found, 438.0772.

**6-Bromo-5,8-dimethoxy-2-methylisoquinolin-1(2H)-one (62) and 6-Bromo-5-hydroxy-8-methoxy-2-methylisoquinolin-1(2H)-one (64).** Concentrated  $\text{H}_2\text{SO}_4$  (10 mL) was added dropwise to **60** (3.05 g, 7.82 mmol) with stirring at 0 °C under  $\text{CaCl}_2$  guard. After the addition was complete, the solution was allowed to warm to rt, then stirred at 50 °C for 24 h, before being diluted with  $\text{H}_2\text{O}$  (30 mL), carefully neutralized with ice-cold sat. aq  $\text{NaHCO}_3$  (~50 mL), then extracted with EtOAc (3  $\times$  20 mL). The extract was dried and evaporated. Precipitation from EtOAc followed by recrystallization from MeOH gave **64** as white plates (0.24 g, 11%), mp 194–197 °C.  $R_f$  (1:19 MeOH/DCM) 0.15. IR (ATR)  $\nu_{\max}$   $\text{cm}^{-1}$ : 3300–2700 (OH), 1643 (C=O).  $^1\text{H}$  NMR (600 MHz, DMSO- $d_6$ ):  $\delta$  9.28 (s, 1H, OH), 7.46 (d,  $J$  = 7.8 Hz, 1H, H3), 7.05 (s, 1H, H7), 6.67 (d,  $J$  = 7.8 Hz, 1H, H4), 3.77 (s, 3H, OMe), 3.38 (s, 3H, NMe).  $^{13}\text{C}$  NMR (150 MHz, DMSO- $d_6$ ):  $\delta$  158.9 (C1), 153.5 (C2 or C5), 141.6 (C2 or C5), 134.4 (C3), 131.2 (C4a or C8a), 114.6 (C4a or C8a), 113.9 (C6), 112.2 (C7), 98.4 (C4), 56.3 (OMe), 36.3 (NMe). HRMS (ESI): calcd for  $\text{C}_{13}\text{H}_{13}^{79}\text{BrN}_2\text{NaO}_3^+$  [ $\text{M} + \text{Na} + \text{MeCN}$ ] $^+$ , 347.0005; found, 347.0002.

The filtrate was evaporated to give isoquinolone **62** as a pale-yellow solid (1.67 g, 72%), mp 118–120 °C.  $R_f$  (1:19 MeOH/DCM) 0.35. IR (ATR)  $\nu_{\max}$   $\text{cm}^{-1}$ : 1656 (C=O).  $^1\text{H}$  NMR (600 MHz, DMSO- $d_6$ ):  $\delta$  7.54 (d,  $J$  = 7.8 Hz, 1H, H3), 7.11 (s, 1H, H7), 6.52 (d,  $J$  = 7.8 Hz, 1H, H4), 3.83 (s, 3H, OMe), 3.75 (s, 3H, OMe), 3.40 (s, 3H, NMe).  $^{13}\text{C}$  NMR (150 MHz):  $\delta$  158.9 (C1), 156.7 (C2 or C5), 144.4 (C2 or C5), 135.9 (C3), 134.4 (C4a or C8a), 119.8 (C4a or C8a), 114.8 (C6), 111.8 (C7), 97.6 (C4), 61.0 (OMe), 56.3 (OMe), 36.5 (NMe). HRMS (ESI): calcd for  $\text{C}_{12}\text{H}_{13}^{79}\text{BrNO}_3^+$  [ $\text{M} + \text{H}$ ] $^+$ , 298.0095; found, 298.0073.

**6-Iodo-5,8-dimethoxy-2-methylisoquinolin-1(2H)-one (63) and 5-Hydroxy-6-iodo-8-methoxy-2-methylisoquinolin-1(2H)-one (65).** Concentrated  $\text{H}_2\text{SO}_4$  (10 mL) was added dropwise to **61** (0.81 g, 1.85 mmol) with stirring at 0 °C under  $\text{CaCl}_2$  guard. After the addition was complete, the solution was allowed to warm to rt, and stirring was

continued at 60 °C for 24 h, before the reaction mixture was diluted with  $\text{H}_2\text{O}$  (30 mL), carefully neutralized with ice cold sat. aq  $\text{NaHCO}_3$  (~50 mL), then extracted with EtOAc (3  $\times$  20 mL). The extract was dried and evaporated, and the residue was subjected to flash chromatography. Elution with EtOAc gave isoquinolone **63** as a pale-yellow solid (0.18 g, 28%), mp 50–52 °C.  $R_f$  (1:19 MeOH/DCM) 0.3. IR (ATR)  $\nu_{\max}$   $\text{cm}^{-1}$ : 1647 (C=O).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ ):  $\delta$  7.50 (d,  $J$  = 9.0 Hz, 1H, H3), 7.23 (s, 1H, H7), 6.47 (d,  $J$  = 9.0 Hz, 1H, H4), 3.80 (s, 3H, OMe), 3.70 (s, 3H, OMe), 3.38 (s, 3H, NMe).  $^{13}\text{C}$  NMR (125 MHz, DMSO- $d_6$ ):  $\delta$  159.1 (C1), 156.6 (C2 or C5), 147.8 (C2 or C5), 135.8 (C3), 133.1 (C4a or C8a), 117.3 (C7), 115.4 (C4a or C8a), 98.0 (C4), 96.6 (C6), 61.0 (OMe), 56.3 (OMe), 36.6 (NMe). HRMS (APCI): calcd for  $\text{C}_{12}\text{H}_{13}\text{INO}_3^+$  [ $\text{M} + \text{H}$ ] $^+$ , 345.9938; found, 345.9935.

Further elution gave **65** (0.26 g, 42%) as a yellow/orange solid, mp 163–166 °C.  $R_f$  (1:19 MeOH/DCM) 0.2. IR (ATR)  $\nu_{\max}$   $\text{cm}^{-1}$ : 3700–2700 (OH), 1646 (C=O).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ ):  $\delta$  9.25 (s, 1H, OH), 7.45 (d,  $J$  = 9.0 Hz, 1H, H3), 7.21 (s, 1H, H7), 6.65 (d,  $J$  = 9.0 Hz, 1H, H4), 3.76 (s, 3H, OMe), 3.38 (s, 3H, NMe).  $^{13}\text{C}$  NMR (125 MHz, DMSO- $d_6$ ):  $\delta$  159.2 (C1), 153.8 (C2 or C5), 144.8 (C2 or C5), 134.4 (C3), 129.9 (C4a or C8a), 118.0 (C7), 115.3 (C4a or C8a), 98.7 (C4), 91.9 (C6), 56.4 (OMe), 36.5 (NMe). HRMS (APCI): calcd for  $\text{C}_{11}\text{H}_{11}\text{INO}_3^+$  [ $\text{M} + \text{H}$ ] $^+$ , 331.9796; found, 331.9778.

**6-Bromo-2-methylisoquinoline-1,5,8(2H)-trione (67).** A solution of CAN (0.29 g, 0.53 mmol) in  $\text{H}_2\text{O}$  (1 mL) was added to a stirred solution of **64** (28 mg, 99  $\mu\text{mol}$ ) in MeCN (8 mL) at –30 °C. The reaction was allowed to warm to –20 °C over 30 min before being diluted with  $\text{H}_2\text{O}$  (20 mL) and extracted with EtOAc (3  $\times$  10 mL). The extract was dried and evaporated to give quinone **67** as a red solid (20 mg, 76%), mp 167–171 °C.  $R_f$  (1:19 MeOH/DCM) 0.15. IR (ATR)  $\nu_{\max}$   $\text{cm}^{-1}$ : 1678 (C=O).  $^1\text{H}$  NMR (600 MHz, DMSO- $d_6$ ):  $\delta$  8.31 (d,  $J$  = 7.2 Hz, 1H, H3), 7.45 (s, 1H, H7), 6.71 (d,  $J$  = 7.2 Hz, 1H, H4), 3.52 (s, 3H, NMe).  $^{13}\text{C}$  NMR (150 MHz):  $\delta$  180.2 (C5 or C8), 178.4 (C5 or C8), 157.3 (C1), 147.4 (C3), 142.6 (C4a or C8a), 141.2 (C7), 134.0 (C4a or C8a), 116.2 (C6), 100.4 (C4), 38.1 (NMe).

**6-Iodo-2-methylisoquinoline-1,5,8(2H)-trione (68).** A solution of CAN (1.65 g, 3.01 mmol) in  $\text{H}_2\text{O}$  (2 mL) was added to a stirred solution of **65** (0.18 g, 0.54 mmol) in MeCN (12 mL) at –30 °C. The reaction was allowed to warm to –20 °C over 20 min before being diluted with  $\text{H}_2\text{O}$  (20 mL) and extracted with EtOAc (3  $\times$  10 mL). The extract was dried and evaporated to give quinone **68** as a red solid (0.10 g, 59%), mp 218–220 °C.  $R_f$  (EtOAc) 0.1. IR (ATR)  $\nu_{\max}$   $\text{cm}^{-1}$ : 1683 (C=O).  $^1\text{H}$  NMR (600 MHz, DMSO- $d_6$ ):  $\delta$  8.27 (d,  $J$  = 6.6 Hz, 1H, H3), 7.69 (s, 1H, H7), 6.69 (d,  $J$  = 6.6 Hz, 1H, H4), 3.51 (s, 3H, NMe).  $^{13}\text{C}$  NMR (150 MHz, DMSO- $d_6$ ):  $\delta$  180.1 (C5 or C8), 179.9 (C5 or C8), 157.4 (C1), 148.9 (C3), 147.3 (C7), 141.3 (C4a or C8a), 116.5 (C4a or C8a), 116.3 (C6), 100.8 (C4), 38.1 (NMe). HRMS (APCI): calcd for  $\text{C}_{10}\text{H}_7\text{INO}_3^+$  [ $\text{M} + \text{H}$ ] $^+$ , 315.9476; found, 315.9465.

**Ethyl 2-(5,8-Dihydroxy-2-methyl-1-oxo-1,2-dihydroisoquinolin-6-yl)-2-(2-nitrophenyl)acetate (70).**  $\text{K}_2\text{CO}_3$  (0.21 g, 1.54 mmol) was added to a stirred solution of **67** (92 mg, 0.34 mmol) and **15** (0.18 g, 0.87 mmol) in DMF (5 mL). The reaction was heated to 45 °C and maintained for 2 h before being cooled, diluted with 1 M HCl (20 mL), and



extracted with EtOAc (3 × 10 mL). The extract was dried and evaporated, and the residue was subjected to flash chromatography. Elution with 3:2 EtOAc/hexanes gave **70** as a yellow-orange solid (39 mg, 29%). <sup>1</sup>H NMR (600 MHz): δ 13.10 (s, 1H, OH), 8.07 (d, *J* = 7.2 Hz, 1H, H3''), 7.44 (dd, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.2 Hz, 1H, H4'' or H5''), 7.42 (dd, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.2 Hz, 1H, H4'' or H5''), 7.22 (d, *J* = 7.2 Hz, 1H, H6''), 7.09 (d, *J* = 7.2 Hz, 1H, H3'), 6.91 (d, *J* = 7.2 Hz, 1H, H4'), 6.34 (s, 1H, H2 or H7'), 5.52 (s, 1H, H2 or H7'), 4.22 (q, *J* = 6.6 Hz, 2H, OCH<sub>2</sub>CH<sub>3</sub>), 3.61 (s, 3H, NMe), 1.20 (t, *J* = 6.6 Hz, 3H, OCH<sub>2</sub>CH<sub>3</sub>). <sup>13</sup>C NMR (150 MHz): δ 170.4 (C1), 165.3 (C1'), 153.3 (C5' or C8'), 149.8 (C5' or C8'), 138.7 (C2''), 133.3 (ArH), 133.2, 132.5, 130.7 (ArH), 128.3 (ArH), 126.4, 125.1, 125.0 (ArH), 119.2, 110.9, 102.5 (ArH), 61.9 (OCH<sub>2</sub>CH<sub>3</sub>), 47.1 (C2), 36.7 (NMe), 14.0 (OCH<sub>2</sub>CH<sub>3</sub>).

## ■ ASSOCIATED CONTENT

### SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsomega.2c02116>.

CIF file for the crystal structure of **35/35a** (CIF)

CIF file for the crystal structure of **53a/53b** (CIF)

CIF file for the crystal structure of **64** (CIF)

CIF file for the crystal structure of **68** (CIF)

<sup>1</sup>H and <sup>13</sup>C spectra annotated with skeleton-numbered structures and general crystallographic methods, tabulated data, and CCDC deposit numbers for compounds **35/35a**, **53a/53b**, **64**, and **68** (PDF)

## ■ AUTHOR INFORMATION

### Corresponding Author

Matthew J. Piggott – Chemistry, School of Molecular Sciences, University of Western Australia, Perth 6009, Australia; [orcid.org/0000-0002-5857-7051](https://orcid.org/0000-0002-5857-7051); Email: [matthew.piggott@uwa.edu.au](mailto:matthew.piggott@uwa.edu.au)

### Authors

Marco Buccini – Chemistry, School of Molecular Sciences, University of Western Australia, Perth 6009, Australia

Louisa Tham – Chemistry, School of Molecular Sciences, University of Western Australia, Perth 6009, Australia

Francis Dhoro – Chemistry, School of Molecular Sciences, University of Western Australia, Perth 6009, Australia

Brian W. Skelton – Chemistry, School of Molecular Sciences, University of Western Australia, Perth 6009, Australia

Craig M. Williams – School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane 4072 Queensland, Australia; [orcid.org/0000-0002-3834-7398](https://orcid.org/0000-0002-3834-7398)

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acsomega.2c02116>

### Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

We thank the UWA Centre for Characterisation, Microscopy and Analysis, in particular Drs Lindsay Byrne and Gareth Nealon for assistance with NMR spectroscopy and Drs Anthony Reeder and Michael Clarke for help with mass spectrometry. The Australian Government is gratefully acknowledged for an Australian Postgraduate Award (M.R.B.) and Research Training Program (RTP) Scholar-

ships (F.D. and L.T.). Waiver of tuition fees (F.D.) and a UWA–UQ Bilateral Research Collaboration Award from the University of Western Australia facilitated this work. C.M.W. thanks the University of Queensland for financial support.

## ■ REFERENCES

- (1) Thale, Z.; Johnson, T.; Tenney, K.; Wenzel, P. J.; Lobkovsky, E.; Clardy, J.; Media, J.; Pietraszkiewicz, H.; Valeriote, F. A.; Crews, P. Structures and cytotoxic properties of sponge-derived bisannulated acridines. *J. Org. Chem.* **2002**, *67*, 9384–9391.
- (2) Inman, W. D.; O'Neill-Johnson, M.; Crews, P. Novel marine sponge alkaloids. 1. Plakinidine A and B, anthelmintic active alkaloids from a Plakortis sponge. *J. Am. Chem. Soc.* **1990**, *112*, 1–4.
- (3) West, R. R.; Mayne, C. L.; Ireland, C. M.; Brinen, L. S.; Clardy, J. Plakinidines: cytotoxic alkaloid pigments from the Fijian sponge Plakortis sp. *Tetrahedron Lett.* **1990**, *31*, 3271–3274.
- (4) Ralifo, P.; Sanchez, L.; Gassner, N. C.; Tenney, K.; Lokey, R. S.; Holman, T. R.; Valeriote, F. A.; Crews, P. Pyrroloacridine Alkaloids from Plakortis quasiamphiasper: Structures and Bioactivity. *J. Nat. Prod.* **2007**, *70*, 95–99.
- (5) Ford, P. W.; Davidson, B. S. Plakinidine, D a new pyrroloacridine alkaloid from the ascidian Didemnum rubeum. *J. Nat. Prod.* **1997**, *60*, 1051–1053.
- (6) Smith, C. J.; Venables, D. A.; Hopmann, C.; Salomon, C. E.; Jompa, J.; Tahir, A.; Faulkner, D. J.; Ireland, C. M. Plakinidine D, a new pyrroloacridine alkaloid from two ascidians of the genus Didemnum. *J. Nat. Prod.* **1997**, *60*, 1048–1050.
- (7) Marshall, K. M.; Barrows, L. R. Biological activities of pyridoacridines. *Nat. Prod. Rep.* **2004**, *21*, 731–751.
- (8) Charyulu, G. A.; McKee, T. C.; Ireland, C. M. Diplamine, a cytotoxic polyaromatic alkaloid from the tunicate Diplosoma sp. *Tetrahedron Lett.* **1989**, *30*, 4201–4202.
- (9) McCarthy, P. J.; Pitts, T. P.; Gunawardana, G. P.; Kelly-Borges, M.; Pomponi, S. Antifungal activity of meridine, a natural product from the marine sponge Corticium sp. *J. Nat. Prod.* **1992**, *55*, 1664–1668.
- (10) Gunawardana, G. P.; Kohmoto, S.; Gunasekera, S. P.; McConnell, O. J.; Koehn, F. E. Dercitine, a new biologically active acridine alkaloid from a deep water marine sponge, Dercitus sp. *J. Am. Chem. Soc.* **1988**, *110*, 4856–4858.
- (11) Copp, B. R.; Kayser, O.; Brun, R.; Kiderlen, A. F. Antiparasitic activity of marine pyridoacridone alkaloids related to the ascididemics. *Planta Med.* **2003**, *69*, 527–531.
- (12) Eder, C.; Schupp, P.; Proksch, P.; Wray, V.; Steube, K.; Mueller, C. E.; Frobenius, W.; Herderich, M.; van Soest, R. W. M. Bioactive pyridoacridine alkaloids from the Micronesian sponge Oceanapia sp. *J. Nat. Prod.* **1998**, *61*, 301–305.
- (13) McDonald, L. A.; Eldredge, G. S.; Barrows, L. R.; Ireland, C. M. Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II. *J. Med. Chem.* **1994**, *37*, 3819–3827.
- (14) de Guzman, F. S.; Carte, B.; Troupe, N.; Faulkner, D. J.; Harper, M. K.; Concepcion, G. P.; Mangalindan, G. C.; Matsumoto, S. S.; Barrows, L. R.; Ireland, C. M. Neoamphimedine: a new pyridoacridine topoisomerase II inhibitor which catenates DNA. *J. Org. Chem.* **1999**, *64*, 1400–1402.
- (15) Tasdemir, D.; Marshall, K. M.; Mangalindan, G. C.; Concepcion, G. P.; Barrows, L. R.; Harper, M. K.; Ireland, C. M. Deoxyamphimedine, a new pyridoacridine alkaloid from two tropical Xestospongia sponges. *J. Org. Chem.* **2001**, *66*, 3246–3248.
- (16) Marshall, K. M.; Matsumoto, S. S.; Holden, J. A.; Concepcion, G. P.; Tasdemir, D.; Ireland, C. M.; Barrows, L. R. The anti-neoplastic and novel topoisomerase II-mediated cytotoxicity of neoamphimedine, a marine pyridoacridine. *Biochem. Pharmacol.* **2003**, *66*, 447–458.



- (17) Kitahara, Y.; Mizuno, T.; Kubo, A. Synthetic studies of benzo[b]pyrrolo[4,3,2-de][1,10]phenanthroline. *Tetrahedron* **2004**, *60*, 4283–4288.
- (18) Fukuyama, T.; Komori, T.; Yokoshima, S. Synthetic studies on plakinidines. *Synlett* **2015**, *26*, 1537–1540.
- (19) Tokuyama, H.; Satoh, T.; Adachi, T.; Okano, K.; Sakata, J. Synthetic studies on plakinidines. *Heterocycles* **2019**, *99*, 310–323.
- (20) Buccini, M.; Jeow, S. Y.; Byrne, L.; Skelton, B. W.; Nguyen, T. M.; Chai, C. L. L.; Piggott, M. J. Bisannulation of 2,3-dichloro-1,4-naphthoquinone with o-nitrophenylacetic acid derivatives: a succinct synthesis of the ABCD ring system of alpinkidine. *Eur. J. Org. Chem.* **2013**, 3232–3240.
- (21) Volvoikar, P. S.; Tilve, S. G.; Zubkov, F. I. A concise approach for the synthesis of the ABCD ring system of alpinkidine. *ChemistrySelect* **2019**, *4*, 7187–7189.
- (22) Cappelli, A.; Gallelli, A.; Manini, M.; Anzini, M.; Mennuni, L.; Makovec, F.; Menziani, M. C.; Alcaro, S.; Ortuso, F.; Vomero, S. Further studies on the interaction of the 5-hydroxytryptamine<sub>3</sub> (5-HT<sub>3</sub>) receptor with arylpiperazine ligands. Development of a new 5-HT<sub>3</sub> receptor ligand showing potent acetylcholinesterase inhibitory properties. *J. Med. Chem.* **2005**, *48*, 3564–3575.
- (23) Lee, H.-J.; Suh, M.-E.; Lee, C.-O. Synthesis and cytotoxicity evaluation of 2-amino- and 2-hydroxy-3-ethoxycarbonyl-N-substituted-benzo[f]indole-4,9-dione derivatives. *Bioorg. Med. Chem.* **2003**, *11*, 1511–1519.
- (24) Salov, B. V.; Shakhnovich, A. I. 4,9-Dihydrobenz[f]indole-4,9-dione derivatives. Synthesis and properties of 2,3,4,9-tetrahydrobenz[f]indole-2,4,9-triones and 2,3,4,9-tetrahydrobenz[f]indole-2,3,4,9-tetrones. *Khim. Geterotsikl. Soedin.* **1976**, 911–914.
- (25) Shakhnovich, A. I. Synthesis of 3-substituted 2-hydroxybenz[f]indolequinones and benz[f]isatinquinone—a new  $\pi$ -acceptor system. *J. Heterocycl. Chem.* **1991**, *28*, 33–39.
- (26) Azadi-Ardakani, M.; Wallace, T. W. 3,6-Dimethoxybenzocyclobutenone: a reagent for quinone synthesis. *Tetrahedron* **1988**, *44*, 5939–5952.
- (27) Cody, J. A.; Ahmed, I.; Tusch, D. J. Studies toward the total synthesis of elefine: an efficient construction of the AB ring system. *Tetrahedron Lett.* **2010**, *51*, 5585–5587.
- (28) Prey, V. Die Spaltung von Phenoläthern mit Pyridinhydrochlorid. *Ber. Dtsch. Chem. Ges. B* **1941**, *74*, 1219–1225.
- (29) De Silva, S. O.; Watanabe, M.; Snieckus, V. General route to anthraquinone natural products via directed metalation of N,N-diethylbenzamides. *J. Org. Chem.* **1979**, *44*, 4802–4808.
- (30) Beer, R. J. S.; Clark, K.; Davenport, H. F.; Robertson, A. Chemistry of the melanins. III. The synthesis of hydroxyindoles from p-benzoquinones. *J. Chem. Soc.* **1951**, 2029–2032.
- (31) Farina, F.; Torres, T. Polycyclic hydroxyquinones. Part III. Synthesis of 6-oxo-5,6,7,8-tetrahydro-1,4-naphthoquinone and derivatives and a new, convenient preparation of o-naphthazarin. *Synthesis* **1980**, 753–755.
- (32) Cassis, R.; Valderrama, J. A. Studies on quinones. XI. Synthesis of quinones from hydroquinones by using manganese dioxide and acid-impregnated manganese dioxide. *Synth. Commun.* **1983**, *13*, 347–356.
- (33) Kloetzel, M. C.; Dayton, R. P.; Abadir, B. Y. Synthetic analogs of cortical hormones. I. Homogentisic acid and  $\alpha$ ,2,5-trihydroxyacetophenone derivatives from 2,5-diacetoxy- $\alpha$ -diazoacetophenone. *J. Org. Chem.* **1955**, *20*, 38–49.
- (34) Shi, S.; Katz, T. J.; Yang, B. V.; Liu, L. Use of thiazyl chlorides, alkyl carbamates, and thionyl chloride to fuse 1,2,5-thiadiazoles to quinones and to oxidize, chlorinate, and aminate them. *J. Org. Chem.* **1995**, *60*, 1285–1297.
- (35) Ferreira, V. F.; Schmitz, F. J. Improved preparation of 5,6-dichlorocyclohex-2-ene-1,4-dione. *Org. Prep. Proced. Int.* **1998**, *30*, 115–116.
- (36) Sy, W.-W.; Lodge, B. A.; By, A. W. Aromatic iodination with iodine and silver sulfate. *Synth. Commun.* **1990**, *20*, 877–880.
- (37) Lanfranchi, D. A.; Cesar-Rodo, E.; Bertrand, B.; Huang, H.-H.; Day, L.; Johann, L.; Elhabiri, M.; Becker, K.; Williams, D. L.; Davioud-Charvet, E. Synthesis and biological evaluation of 1,4-naphthoquinones and quinoline-5,8-diones as antimalarial and schistosomicidal agents. *Org. Biomol. Chem.* **2012**, *10*, 6375–6387.
- (38) Lüttringhaus, A.; Gralheer, H. Über eine neue Art atropisomerer Verbindungen. *Justus Liebigs Ann. Chem.* **1942**, 550, 67–98.
- (39) Li, C.; Lobkovsky, E.; Porco, J. A., Jr. Total synthesis of ( $\pm$ )-torreyanic acid. *J. Am. Chem. Soc.* **2000**, *122*, 10484–10485.
- (40) Li, C.; Johnson, R. P.; Porco, J. A., Jr. Total synthesis of the quinone epoxide dimer (+)-torreyanic acid: application of a biomimetic oxidation/electrocyclization/Diels-Alder dimerization cascade. *J. Am. Chem. Soc.* **2003**, *125*, 5095–5106.
- (41) Bergman, J.; Mason, J.; Janosik, T. A new approach to methoxyisatins leading to the total synthesis of ophiurodine and other hydroxytryptanthrins. *Synthesis* **2009**, 3642–3648.
- (42) Moliterno, M.; Cari, R.; Puglisi, A.; Antenucci, A.; Sperandio, C.; Moretti, E.; Di Sabato, A.; Salvio, R.; Bella, M. Quinine-catalyzed asymmetric synthesis of 2,2'-binaphthol-type biaryls under mild reaction conditions. *Angew. Chem., Int. Ed.* **2016**, *55*, 6525–6529.
- (43) Chen, Y.-H.; Cheng, D.-J.; Zhang, J.; Wang, Y.; Liu, X.-Y.; Tan, B. Atroposelective synthesis of axially chiral biaryldiols via organocatalytic arylation of 2-naphthols. *J. Am. Chem. Soc.* **2015**, *137*, 15062–15065.
- (44) Barker, D.; Brimble, M. A.; Do, P.; Turner, P. Addition of silyloxydienes to 2,6-dibromo-1,4-benzoquinone: an approach to highly oxygenated bromonaphthoquinones for the synthesis of thysanone. *Tetrahedron* **2003**, *59*, 2441–2449.
- (45) Lyubchanskaya, V. M.; Alekseeva, L. M.; Granik, V. G. Synthesis of 2-(1-ethoxycarbonyl-2-aminopropen-1-yl)-3,5-dibromohydroquinones. *Khim.-Farm. Zh.* **1992**, *26*, 55–57.
- (46) Hegedus, L. S.; Mulhern, T. A.; Mori, A. Palladium(0)-catalyzed syntheses of indoloquinones. *J. Org. Chem.* **1985**, *50*, 4282–4288.
- (47) Grandmaison, J. L.; Brassard, P. Reactions of ketene acetals. IX. The synthesis of naphthoquinones from benzoquinones. *Tetrahedron* **1977**, *33*, 2047–2053.
- (48) Dhoro, F.; Parkin-Gibbs, J.; McIlldowie, M.; Skelton, B. W.; Piggott, M. J. Confirmation of the revised structure of samoquasine A and a proposed structural revision of cherimoline. *J. Nat. Prod.* **2018**, *81*, 1658–1665.
- (49) Kitasato, Z.; Sone, C. The synthesis of N-methylhydroxy-naphthindolequinone and N-methylnaphthisatinquinone. *Bull. Chem. Soc. Jpn.* **1930**, *5*, 348–354.
- (50) Jones, R. G.; Kornfeld, E. C.; McLaughlin, K. C.; Anderson, R. C.; Imidazoles, I. V. The synthesis and antithyroid activity of some 1-substituted-2-mercaptoimidazoles. *J. Am. Chem. Soc.* **1949**, *71*, 4000–4002.
- (51) Hubig, S. M.; Jung, W.; Kochi, J. K. Cation radicals as intermediates in aromatic halogenation with iodine monochloride: solvent and salt effects on the competition between chlorination and iodination. *J. Org. Chem.* **1994**, *59*, 6233–6244.
- (52) Gothard, C. M.; Rao, N. A.; Nowick, J. S. Nanometer-sized Amino acids for the synthesis of nanometer-scale water-soluble molecular rods of preciselength. *J. Am. Chem. Soc.* **2007**, *129*, 7272.
- (53) Sato, T. Estrogenic biphenyls. VII. Preparation and estrogenic action of methoxyl derivatives of 4-methoxybiphenyl-4'-carboxylic acid. *Bull. Chem. Soc. Jpn.* **1959**, *32*, 1292.